Can analysts adopt a bullish outlook for Concert Pharmaceuticals, Inc. (NASDAQ:CNCE)?

August 9, 2018 - By Kristin Houston

Concert Pharmaceuticals, Inc. (NASDAQ:CNCE) LogoInvestors sentiment decreased to 1.37 in Q1 2018. Its down 1.25, from 2.62 in 2017Q4. It fall, as 13 investors sold Concert Pharmaceuticals, Inc. shares while 33 reduced holdings. 29 funds opened positions while 34 raised stakes. 16.64 million shares or 7.42% more from 15.49 million shares in 2017Q4 were reported.
Aureus Asset Mgmt Ltd Liability holds 15,625 shares. Goldman Sachs holds 91,202 shares. Citigroup Inc reported 3,781 shares stake. Barclays Public Ltd Co has 8,263 shares for 0% of their portfolio. Pub Employees Retirement Of Ohio stated it has 0% in Concert Pharmaceuticals, Inc. (NASDAQ:CNCE). California Employees Retirement System stated it has 0% in Concert Pharmaceuticals, Inc. (NASDAQ:CNCE). State Street Corp reported 381,912 shares. Parametric, a Washington-based fund reported 86,671 shares. New York-based Morgan Stanley has invested 0% in Concert Pharmaceuticals, Inc. (NASDAQ:CNCE). Voya Investment Management Ltd Liability Co has invested 0% in Concert Pharmaceuticals, Inc. (NASDAQ:CNCE). Franklin Res owns 576,900 shares or 0.01% of their US portfolio. 1.60 million were reported by Blackrock. Ghost Tree Capital Limited Liability Co owns 350,000 shares or 1.62% of their US portfolio. Zurcher Kantonalbank (Zurich Cantonalbank) has invested 0% in Concert Pharmaceuticals, Inc. (NASDAQ:CNCE). Renaissance Techs owns 494,200 shares.

Since April 17, 2018, it had 0 insider buys, and 2 sales for $775,097 activity. Stuart Nancy sold $561,587 worth of stock.

Concert Pharmaceuticals, Inc. (NASDAQ:CNCE) Ratings Coverage

Among 2 analysts covering Concert Pharmaceuticals (NASDAQ:CNCE), 2 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Concert Pharmaceuticals had 3 analyst reports since March 2, 2018 according to SRatingsIntel. The rating was upgraded by Mizuho on Friday, March 9 to “Buy”. The company was maintained on Friday, May 4 by H.C. Wainwright. On Friday, March 2 the stock rating was maintained by H.C. Wainwright with “Buy”. Below is a list of Concert Pharmaceuticals, Inc. (NASDAQ:CNCE) latest ratings and price target changes.

04/05/2018 Broker: H.C. Wainwright Old Rating: Buy New Rating: Buy Old Target: $25 New Target: $26 Maintain
09/03/2018 Broker: Mizuho Rating: Buy New Target: $27.0 Upgrade
02/03/2018 Broker: H.C. Wainwright Old Rating: Buy New Rating: Buy Old Target: $21 New Target: $25 Maintain

The stock increased 0.42% or $0.07 during the last trading session, reaching $16.69. About 17,248 shares traded. Concert Pharmaceuticals, Inc. (NASDAQ:CNCE) has risen 41.24% since August 9, 2017 and is uptrending. It has outperformed by 28.67% the S&P500.

Concert Pharmaceuticals, Inc. operates as a clinical stage biopharmaceutical company. The company has market cap of $390.80 million. It discovers and develops novel small molecule drugs for use in the treatment of various pulmonary diseases, including cystic fibrosis, autoimmune and inflammatory diseases, and central nervous systems disorders. It has a 3.84 P/E ratio. The companyÂ’s clinical-stage product candidates include AVP-786, which is in Phase 3 clinical trials for the treatment of neurologic and psychiatric disorders, including agitation associated with AlzheimerÂ’s disease; and CTP-656, which is in Phase 2 clinical trials to treat cystic fibrosis.

More notable recent Concert Pharmaceuticals, Inc. (NASDAQ:CNCE) news were published by: Streetinsider.com which released: “Concert Pharma (CNCE) Tops Q2 EPS by 5c” on August 02, 2018, also Businesswire.com with their article: “Concert Pharmaceuticals to Report Second Quarter 2018 Financial Results on August 2, 2018” published on July 26, 2018, Seekingalpha.com published: “Concert Pharmaceuticals Inc.’s (CNCE) CEO Roger Tung on Q2 2018 Results – Earnings Call Transcript” on August 04, 2018. More interesting news about Concert Pharmaceuticals, Inc. (NASDAQ:CNCE) were released by: Businesswire.com and their article: “Concert Pharmaceuticals Reports Second Quarter 2018 Financial Results and Provides Company Update” published on August 02, 2018 as well as Globenewswire.com‘s news article titled: “Consolidated Research: 2018 Summary Expectations for Independent Bank Group, Concert Pharmaceuticals, Bank of …” with publication date: August 07, 2018.

Concert Pharmaceuticals, Inc. (NASDAQ:CNCE) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.